Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

21 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Your Health and Well- Being Week 36 Mepolizumab HES NCT00086658 - Your Health and Well- Being Week 36

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Health assessment questionnaire score quality of life
Study part: Your Health and Well- Being Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 36 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 36

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 36

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Your Health and Well- Being Week 38 Mepolizumab HES NCT00086658 - Your Health and Well- Being Week 38

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Health assessment questionnaire score quality of life
Study part: Your Health and Well- Being Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 32 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 32

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 38 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 38

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 38 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 38

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Day 1 Week 8 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Day 1 Week 8

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 12 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 12

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 12 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 12

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Your Health and Well- Being Week 12 Mepolizumab HES NCT00086658 - Your Health and Well- Being Week 12

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Health assessment questionnaire score quality of life
Study part: Your Health and Well- Being Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 28 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 28

- 05/06/2017 - 1 Formulário, 1 Grupo de itens, 2 Elementos de dados, 1 Idioma
Grupo de itens: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 28.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial